Agomab Advances AGMB-447 Into Phase 2 for IPF
ANTWERP, Belgium — September 14, 2026 Agomab Therapeutics NV announced positive Phase 1 results for AGMB-447, an investigational inhaled,...
Pulmonary Fibrosis
Advertisement
Avalyn Pharma Presents New AP01 Data in Pulmonary Fibrosis
BOSTON — September 8, 2026 Avalyn Pharma presented new data at the European Respiratory Society (ERS) International Congress 2026...
United Therapeutics FDA Accepts Tyvaso sNDA for IPF
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 United Therapeutics Corporation announced that the U.S. Food...
Rein Therapeutics Gains FDA Fast Track for LTI-03 in IPF
Austin, Texas, August 20, 2026 Rein Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Evaxion Advances AI-Designed EVX-05 Brain Cancer Vaccine
Copenhagen, Denmark — August 17, 2026 Evaxion A/S has expanded and refocused its cancer vaccine pipeline with EVX-05, an...
Advertisements
United Therapeutics Completes TETON-PPF Phase 3 Enrollment
Silver Spring, Maryland & Research Triangle Park, North Carolina — August 17, 2026 United Therapeutics Corporation announced the full...
MannKind Reports Positive Phase 1b INFLO-1 IPF Results
Danbury, Conn. & Westlake Village, Calif., July 29, 2026 MannKind Corporation announced positive topline results from its Phase 1b...
Rein Therapeutics Expands Phase 2 RENEW Trial Across Five Countries
Austin, Texas, USA | July 21, 2026 Rein Therapeutics announced that its Phase 2 RENEW clinical trial evaluating the...
Boehringer Ingelheim Wins EU Approval for JASCAYD
INGELHEIM, Germany, July 17, 2026 Boehringer Ingelheim has announced that the European Commission (EC) has granted marketing authorization for...
Celea Doses First Patient in Phase 3 SURPASS-IPF Trial
BOSTON, July 13, 2026 Celea Therapeutics announced that the first patient has been dosed in the global Phase 3...
Advertisement
